Predictive values of D-dimer assay, GRACE scores and TIMI scores for adverse outcome in patients with non-ST-segment elevation myocardial infarction
Loading...
Files
Date
2017
Journal Title
Journal ISSN
Volume Title
Publisher
Dove Medical Press Ltd
Access Rights
info:eu-repo/semantics/openAccess
Abstract
Purpose: To determine the predictive values of D-dimer assay, Global Registry of Acute Coronary Events (GRACE) and Thrombolysis in Myocardial Infarction (TIMI) risk scores for adverse outcome in patients with non-ST-segment elevation myocardial infarction (NSTEMI). Patients and methods: A total of 234 patients (mean age: 57.2 +/- 11.7 years, 75.2% were males) hospitalized with NSTEMI were included. Data on D-dimer assay, GRACE and TIMI risk scores were recorded. Logistic regression analysis was conducted to determine the risk factors predicting increased mortality. Results: Median D-dimer levels were 349.5 (48.0-7,210.0) ng/mL, the average TIMI score was 3.2 +/- 1.2 and the GRACE score was 90.4 +/- 27.6 with high GRACE scores (>118) in 17.5% of patients. The GRACE score was correlated positively with both the D-dimer assay (r= 0.215, P= 0.01) and TIMI scores (r= 0.504, P= 0.000). Multivariate logistic regression analysis revealed that higher creatinine levels (odds ratio = 18.465, 95% confidence interval: 1.059-322.084, P= 0.046) constituted the only significant predictor of increased mortality risk with no predictive values for age, D-dimer assay, ejection fraction, glucose, hemoglobin A1c, sodium, albumin or total cholesterol levels for mortality. Conclusion: Serum creatinine levels constituted the sole independent determinant of mortality risk, with no significant values for D-dimer assay, GRACE or TIMI scores for predicting the risk of mortality in NSTEMI patients.
Description
Ozyilmaz, Sinem/0000-0003-4829-8400
WOS: 000397951200001
PubMed: 28408834
WOS: 000397951200001
PubMed: 28408834
Keywords
acute coronary syndrome, non-ST-segment elevation myocardial infarction, GRACE score, D-dimer assay, TIMI score
Journal or Series
Therapeutics And Clinical Risk Management
WoS Q Value
Q3
Scopus Q Value
N/A
Volume
13
